import type { CompetitorRecord } from './competitor-database';

export const SPECIALTY_COMPETITORS_2: CompetitorRecord[] = [
  // ─── Geographic Atrophy ───────────────────────────────────────────────
  {
    asset_name: 'Syfovre',
    generic_name: 'pegcetacoplan',
    company: 'Apellis Pharmaceuticals',
    indication: 'Geographic Atrophy',
    indication_specifics: 'Complement-mediated geographic atrophy secondary to age-related macular degeneration',
    mechanism: 'Complement C3 inhibitor; blocks central complement component C3 to prevent downstream activation of both C3a and C5a pathways',
    mechanism_category: 'complement_inhibitor',
    molecular_target: 'C3',
    phase: 'Approved',
    primary_endpoint: 'Change in GA lesion area by fundus autofluorescence at 12 months',
    key_data: 'OAKS/DERBY Phase 3: 22% and 18% reduction in GA growth rate vs sham at 24 months with monthly dosing. First FDA-approved treatment for GA (Feb 2023).',
    line_of_therapy: 'First-line',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'First-ever approved therapy for GA, establishing treatment paradigm',
      'Robust efficacy demonstrated across two pivotal Phase 3 trials',
      'Targets upstream C3, providing broad complement pathway inhibition',
    ],
    weaknesses: [
      'Intravitreal injection burden with monthly or every-other-month dosing',
      'Risk of ocular inflammation and endophthalmitis associated with complement inhibition',
      'Modest absolute reduction in lesion growth may limit perceived clinical benefit',
    ],
    source: 'Apellis Pharmaceuticals 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Izervay',
    generic_name: 'avacincaptad pegol',
    company: 'Iveric Bio/Astellas',
    indication: 'Geographic Atrophy',
    indication_specifics: 'Geographic atrophy secondary to age-related macular degeneration',
    mechanism: 'Complement C5 inhibitor; anti-C5 aptamer that blocks cleavage of C5 into C5a and C5b fragments',
    mechanism_category: 'complement_inhibitor',
    molecular_target: 'C5',
    phase: 'Approved',
    primary_endpoint: 'Change in GA lesion area by fundus autofluorescence at 12 months',
    key_data: 'GATHER1/GATHER2 Phase 3: ~35% reduction in GA growth rate vs sham at 12 months with monthly intravitreal injection. FDA approved August 2023.',
    line_of_therapy: 'First-line',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Strong growth rate reduction of ~35% at 12 months, numerically superior to competitor',
      'Monthly-only dosing provides consistent treatment schedule',
      'Favorable safety profile with lower rates of inflammation vs C3 inhibition',
    ],
    weaknesses: [
      'Requires monthly intravitreal injections with no extended dosing option approved',
      'C5-targeted approach leaves upstream complement activation unchecked',
      'Entering market second behind Syfovre limits first-mover advantage',
    ],
    source: 'Astellas 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'ANX007',
    company: 'Annexon Biosciences',
    indication: 'Geographic Atrophy',
    indication_specifics: 'Geographic atrophy secondary to age-related macular degeneration targeting classical complement pathway',
    mechanism: 'Anti-C1q antibody; inhibits the classical complement pathway at its initiating step',
    mechanism_category: 'complement_inhibitor',
    molecular_target: 'C1q',
    phase: 'Phase 3',
    primary_endpoint: 'Change in GA lesion area by fundus autofluorescence',
    key_data: 'Phase 2 ARCHER study showed dose-dependent reduction in GA lesion growth; advanced to Phase 3 APEX trial with intravitreal administration.',
    line_of_therapy: 'First-line',
    nct_ids: ['NCT05839041'],
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'First-in-class C1q inhibitor targeting the most upstream initiator of the classical pathway',
      'Differentiated mechanism may offer complementary or superior efficacy to C3/C5 inhibitors',
      'Potential for improved safety by selectively blocking classical pathway while preserving alternative pathway',
    ],
    weaknesses: [
      'Late to market with two complement inhibitors already approved',
      'Phase 3 data not yet available, creating significant development risk',
      'Narrower pathway inhibition may be insufficient if alternative pathway drives disease progression',
    ],
    source: 'Annexon Biosciences 2024',
    last_updated: '2025-01-15',
  },

  // ─── Glaucoma ─────────────────────────────────────────────────────────
  {
    asset_name: 'Vyzulta',
    generic_name: 'latanoprostene bunod',
    company: 'Bausch + Lomb',
    indication: 'Glaucoma',
    indication_specifics: 'Reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension',
    mechanism: 'Prostaglandin analog with nitric oxide-donating moiety; enhances both uveoscleral and trabecular meshwork outflow',
    mechanism_category: 'prostaglandin_no_donor',
    phase: 'Approved',
    primary_endpoint: 'Reduction in intraocular pressure (IOP) at multiple timepoints',
    key_data: 'APOLLO/LUNAR Phase 3: Achieved significantly greater IOP reduction vs timolol 0.5% at all timepoints. Demonstrated up to 9 mmHg IOP reduction from baseline.',
    line_of_therapy: 'First-line',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Dual mechanism (prostaglandin + NO donor) provides additional IOP lowering vs standard prostaglandins',
      'Once-daily dosing with well-established prostaglandin tolerability profile',
      'Targets both uveoscleral and trabecular outflow pathways simultaneously',
    ],
    weaknesses: [
      'Competes in crowded prostaglandin analog market with multiple generics available',
      'Side effect profile includes iris pigmentation and periorbital changes common to prostaglandins',
      'Incremental IOP benefit over generic latanoprost may not justify cost premium',
    ],
    source: 'Bausch + Lomb 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Rhopressa',
    generic_name: 'netarsudil',
    company: 'Aerie Pharmaceuticals/Alcon',
    indication: 'Glaucoma',
    indication_specifics: 'Reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension',
    mechanism: 'Rho kinase (ROCK) inhibitor; increases trabecular meshwork outflow and reduces episcleral venous pressure and aqueous humor production',
    mechanism_category: 'rho_kinase_inhibitor',
    phase: 'Approved',
    primary_endpoint: 'Reduction in intraocular pressure (IOP)',
    key_data: 'ROCKET Phase 3 trials: Non-inferior to timolol in patients with baseline IOP <25 mmHg. Triple mechanism of action targeting trabecular outflow, EVP, and aqueous production.',
    line_of_therapy: 'First-line or adjunctive',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'First-in-class ROCK inhibitor with novel triple mechanism of action',
      'Directly targets trabecular meshwork, the primary site of outflow resistance',
      'Complementary mechanism allows effective combination with prostaglandin analogs',
    ],
    weaknesses: [
      'Conjunctival hyperemia reported in ~50% of patients, limiting tolerability',
      'Lower absolute IOP reduction compared to prostaglandin analogs',
      'Cornea verticillata (whorl-like corneal deposits) reported in some patients',
    ],
    source: 'Alcon 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'iDose TR',
    generic_name: 'travoprost intracameral implant',
    company: 'Glaukos',
    indication: 'Glaucoma',
    indication_specifics: 'Reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension via sustained-release intracameral implant',
    mechanism: 'Sustained-release travoprost implant placed in the anterior chamber; continuously delivers prostaglandin analog to target tissue',
    mechanism_category: 'prostaglandin_implant',
    phase: 'Approved',
    primary_endpoint: 'IOP reduction non-inferior to timolol at 12 months',
    key_data: 'Phase 3 pivotal trial demonstrated sustained IOP reduction non-inferior to timolol over 12 months. FDA approved December 2023 as first intracameral sustained-release glaucoma implant.',
    line_of_therapy: 'First-line',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Eliminates daily drop adherence burden with sustained drug delivery for up to 12 months',
      'First-in-class intracameral implant offering paradigm shift in glaucoma management',
      'Consistent drug delivery avoids the peak-trough variability of topical dosing',
    ],
    weaknesses: [
      'Requires in-office implantation procedure with associated procedural risks',
      'Limited long-term data on repeated implantation cycles and cumulative safety',
      'Higher upfront cost compared to generic topical prostaglandin drops',
    ],
    source: 'Glaukos 2024',
    last_updated: '2025-01-15',
  },

  // ─── Retinitis Pigmentosa ─────────────────────────────────────────────
  {
    asset_name: 'Luxturna',
    generic_name: 'voretigene neparvovec',
    company: 'Spark Therapeutics/Roche',
    indication: 'Retinitis Pigmentosa',
    indication_specifics: 'RPE65 mutation-associated retinal dystrophy including retinitis pigmentosa and Leber congenital amaurosis',
    mechanism: 'AAV2-based gene therapy delivering functional RPE65 gene to retinal pigment epithelium cells via subretinal injection',
    mechanism_category: 'gene_therapy',
    molecular_target: 'RPE65',
    phase: 'Approved',
    primary_endpoint: 'Multi-luminance mobility testing (MLMT) score change',
    key_data: 'Phase 3: Significant improvement in functional vision by MLMT at 1 year. First FDA-approved gene therapy for genetic disease (Dec 2017). Durable efficacy demonstrated at 4+ years.',
    line_of_therapy: 'First-line for RPE65-confirmed patients',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'First FDA-approved gene therapy for inherited retinal disease with demonstrated durable benefit',
      'One-time treatment paradigm with long-lasting visual improvement',
      'Clear biomarker-defined patient population (RPE65 mutations) enables precision targeting',
    ],
    weaknesses: [
      'Limited to the small subset of RP patients with biallelic RPE65 mutations (~1-2% of RP)',
      'Requires complex subretinal surgery with associated procedural risks',
      'Very high cost (~$850K) limits access and creates reimbursement challenges',
    ],
    source: 'Spark Therapeutics/Roche 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'AGTC-501',
    company: 'Beacon Therapeutics',
    indication: 'Retinitis Pigmentosa',
    indication_specifics: 'X-linked retinitis pigmentosa caused by RPGR gene mutations',
    mechanism: 'AAV-based gene therapy delivering functional RPGR gene to photoreceptor cells via subretinal injection',
    mechanism_category: 'gene_therapy',
    molecular_target: 'RPGR',
    phase: 'Phase 1/2',
    primary_endpoint: 'Safety and change in retinal sensitivity by microperimetry',
    key_data: 'Phase 1/2 SKYLINE study showed improvements in retinal sensitivity in treated eyes vs untreated controls. Dose-dependent efficacy signals observed across multiple visual function endpoints.',
    line_of_therapy: 'First-line for RPGR-confirmed patients',
    nct_ids: ['NCT03316560'],
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'Targets XLRP which represents the most severe and rapidly progressive form of RP',
      'RPGR mutations account for ~70% of X-linked RP cases, a meaningful patient subset',
      'One-time gene therapy approach could halt or reverse disease progression',
    ],
    weaknesses: [
      'Early-stage clinical development with no pivotal data yet available',
      'Subretinal delivery requires vitrectomy surgery in patients with already compromised retinas',
      'Multiple competing RPGR gene therapy programs from 4D Molecular and others',
    ],
    source: 'Beacon Therapeutics 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'jCyte retinal progenitor cells',
    company: 'jCyte',
    indication: 'Retinitis Pigmentosa',
    indication_specifics: 'Non-gene-specific retinitis pigmentosa targeting photoreceptor neuroprotection',
    mechanism: 'Intravitreal injection of human retinal progenitor cells (hRPCs) that secrete neurotrophic factors to protect remaining photoreceptors',
    mechanism_category: 'cell_therapy',
    phase: 'Phase 2',
    primary_endpoint: 'Best-corrected visual acuity (BCVA) change from baseline',
    key_data: 'Phase 2b jCyte-009 study showed trends toward improved visual acuity and visual field in treated patients. Mutation-agnostic approach applicable across RP genotypes.',
    line_of_therapy: 'Adjunctive neuroprotection',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'Mutation-agnostic mechanism applicable to all genetic forms of RP, vastly expanding addressable population',
      'Intravitreal delivery is less invasive than subretinal gene therapy surgery',
      'Neuroprotective approach may preserve residual vision regardless of underlying genetic cause',
    ],
    weaknesses: [
      'Cell therapy manufacturing complexity and batch-to-batch consistency challenges',
      'May require repeat dosing as transplanted cells are not permanently integrated',
      'Phase 2 results showed trends but not statistically robust efficacy signals',
    ],
    source: 'jCyte 2024',
    last_updated: '2025-01-15',
  },

  // ─── Idiopathic Pulmonary Fibrosis ────────────────────────────────────
  {
    asset_name: 'Ofev',
    generic_name: 'nintedanib',
    company: 'Boehringer Ingelheim',
    indication: 'Idiopathic Pulmonary Fibrosis',
    indication_specifics: 'Treatment of idiopathic pulmonary fibrosis to slow disease progression and FVC decline',
    mechanism: 'Triple angiokinase inhibitor targeting VEGFR, FGFR, and PDGFR tyrosine kinases involved in fibrotic pathways',
    mechanism_category: 'tki_multikinase',
    molecular_target: 'VEGFR/FGFR/PDGFR',
    phase: 'Approved',
    primary_endpoint: 'Annual rate of decline in forced vital capacity (FVC)',
    key_data: 'INPULSIS-1/2 Phase 3: Reduced annual rate of FVC decline by ~50% vs placebo (-114 mL/yr vs -240 mL/yr). Consistent benefit across subgroups.',
    line_of_therapy: 'First-line',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Well-established efficacy with consistent ~50% reduction in FVC decline across trials',
      'Broad label expansion to other progressive fibrosing ILDs and SSc-ILD',
      'Oral dosing with twice-daily regimen and manageable safety profile',
    ],
    weaknesses: [
      'Gastrointestinal side effects (diarrhea in ~62%) significantly impact tolerability and adherence',
      'Hepatotoxicity risk requires regular liver function monitoring',
      'Slows but does not halt or reverse fibrotic progression',
    ],
    source: 'Boehringer Ingelheim 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Esbriet',
    generic_name: 'pirfenidone',
    company: 'Roche/Genentech',
    indication: 'Idiopathic Pulmonary Fibrosis',
    indication_specifics: 'Treatment of idiopathic pulmonary fibrosis to reduce disease progression',
    mechanism: 'Antifibrotic agent with pleiotropic effects including inhibition of TGF-beta, reduction of fibroblast proliferation, and anti-inflammatory properties',
    mechanism_category: 'antifibrotic',
    phase: 'Approved',
    primary_endpoint: 'Change in percent predicted FVC or FVC decline over 52 weeks',
    key_data: 'ASCEND Phase 3: Reduced proportion of patients with >=10% FVC decline or death by 48% vs placebo. Pooled analysis with CAPACITY trials confirmed mortality benefit.',
    line_of_therapy: 'First-line',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Longest clinical experience among approved IPF therapies with extensive real-world safety data',
      'Pooled analyses suggest potential mortality benefit beyond FVC stabilization',
      'Generic versions now available in some markets, improving access and affordability',
    ],
    weaknesses: [
      'Three-times-daily dosing with food requirement reduces patient convenience',
      'Photosensitivity and GI side effects (nausea, rash) affect adherence',
      'Like nintedanib, slows but does not arrest or reverse disease progression',
    ],
    source: 'Roche 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Nerandomilast',
    company: 'Boehringer Ingelheim',
    indication: 'Idiopathic Pulmonary Fibrosis',
    indication_specifics: 'Treatment of idiopathic pulmonary fibrosis via selective PDE4B inhibition to reduce inflammation and fibrosis',
    mechanism: 'Selective phosphodiesterase 4B (PDE4B) inhibitor that reduces profibrotic and proinflammatory signaling',
    mechanism_category: 'pde4b_inhibitor',
    phase: 'Phase 3',
    primary_endpoint: 'Annual rate of decline in FVC over 52 weeks',
    key_data: 'Phase 2 showed dose-dependent reduction in FVC decline with acceptable tolerability. Phase 3 FIBRONEER-IPF and FIBRONEER-ILD trials ongoing with topline results expected 2025.',
    line_of_therapy: 'First-line or add-on to standard antifibrotics',
    nct_ids: ['NCT05321069'],
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Novel oral mechanism with potential for combination use alongside existing antifibrotics',
      'PDE4B selectivity may reduce class-related GI side effects seen with pan-PDE4 inhibitors',
      'Same sponsor as Ofev, enabling efficient development and potential combo strategy',
    ],
    weaknesses: [
      'Phase 3 results not yet reported, creating significant clinical and regulatory risk',
      'PDE4 inhibitor class carries known risks of nausea, diarrhea, and weight loss',
      'Incremental benefit over existing approved antifibrotics remains unproven',
    ],
    source: 'Boehringer Ingelheim 2024',
    last_updated: '2025-01-15',
  },

  // ─── Severe Asthma ────────────────────────────────────────────────────
  {
    asset_name: 'Dupixent',
    generic_name: 'dupilumab',
    company: 'Sanofi/Regeneron',
    indication: 'Severe Asthma',
    indication_specifics: 'Moderate-to-severe eosinophilic asthma or oral corticosteroid-dependent asthma in patients aged 6+ years',
    mechanism: 'Monoclonal antibody targeting IL-4 receptor alpha subunit, blocking both IL-4 and IL-13 signaling in type 2 inflammation',
    mechanism_category: 'anti_il4_il13',
    molecular_target: 'IL-4Ra',
    phase: 'Approved',
    primary_endpoint: 'Annualized rate of severe asthma exacerbations',
    key_data: 'LIBERTY ASTHMA Phase 3: 70% reduction in exacerbations in high-eosinophil patients. Significant FEV1 improvement (+340 mL). Enabled OCS dose reduction in steroid-dependent patients.',
    line_of_therapy: 'Add-on maintenance for moderate-to-severe type 2 asthma',
    partner: 'Regeneron',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'Broadest type 2 coverage blocking both IL-4 and IL-13 with robust exacerbation reduction',
      'Significant lung function improvement (FEV1) in addition to exacerbation benefit',
      'Multi-indication franchise (atopic dermatitis, CRSwNP, COPD) builds extensive safety database',
    ],
    weaknesses: [
      'Subcutaneous injection every 2 weeks reduces convenience vs potential oral therapies',
      'Transient hypereosinophilia reported in a subset of patients after treatment initiation',
      'Premium biologic pricing creates access barriers in cost-sensitive healthcare systems',
    ],
    source: 'Sanofi/Regeneron 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Tezspire',
    generic_name: 'tezepelumab',
    company: 'AstraZeneca/Amgen',
    indication: 'Severe Asthma',
    indication_specifics: 'Severe asthma across inflammatory phenotypes, not limited to eosinophilic or type 2 biomarker-high patients',
    mechanism: 'Monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), an upstream epithelial cytokine that initiates multiple inflammatory cascades',
    mechanism_category: 'tslp_inhibitor',
    molecular_target: 'TSLP',
    phase: 'Approved',
    primary_endpoint: 'Annualized rate of severe asthma exacerbations',
    key_data: 'NAVIGATOR Phase 3: 56% reduction in exacerbations in overall population; 70% in high-eosinophil subgroup. First biologic to show efficacy regardless of baseline eosinophil or FeNO levels.',
    line_of_therapy: 'Add-on maintenance for severe asthma',
    partner: 'Amgen',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Broadest patient eligibility among asthma biologics — effective across all inflammatory phenotypes',
      'Upstream TSLP mechanism addresses the initiating trigger of multiple inflammatory cascades',
      'No biomarker requirement for prescribing simplifies treatment decisions',
    ],
    weaknesses: [
      'Numerically lower exacerbation reduction in biomarker-high patients compared to IL-4/IL-5 targeted therapies',
      'Monthly subcutaneous injection; no self-administration device advantage vs competitors',
      'Lacks OCS-sparing pivotal data that competitors like Dupixent have demonstrated',
    ],
    source: 'AstraZeneca 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Itepekimab',
    company: 'Sanofi/Regeneron',
    indication: 'Severe Asthma',
    indication_specifics: 'Moderate-to-severe asthma, including patients with type 2-low inflammation',
    mechanism: 'Monoclonal antibody targeting interleukin-33 (IL-33), an upstream alarmin cytokine released by epithelial cells upon damage or stress',
    mechanism_category: 'anti_il33',
    molecular_target: 'IL-33',
    phase: 'Phase 3',
    primary_endpoint: 'Annualized rate of asthma exacerbations',
    key_data: 'Phase 2: Showed efficacy as monotherapy in former smokers with moderate-to-severe asthma. Phase 3 LIBERTY-ASTHMA trials evaluating monotherapy and combination with dupilumab.',
    line_of_therapy: 'Add-on maintenance therapy',
    partner: 'Regeneron',
    nct_ids: ['NCT04507139'],
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Upstream alarmin target may address type 2-low/non-eosinophilic asthma, an unmet need',
      'Potential for combination with dupilumab to provide enhanced type 2 pathway blockade',
      'Backed by Sanofi/Regeneron expertise and infrastructure in respiratory biologics',
    ],
    weaknesses: [
      'Phase 2 monotherapy efficacy was limited to former-smoker subgroup, raising generalizability questions',
      'Competing with multiple approved asthma biologics in an increasingly crowded market',
      'Phase 3 results pending; unclear differentiation vs Tezspire in broad asthma population',
    ],
    source: 'Sanofi/Regeneron 2024',
    last_updated: '2025-01-15',
  },

  // ─── Chronic Obstructive Pulmonary Disease ────────────────────────────
  {
    asset_name: 'Dupixent',
    generic_name: 'dupilumab',
    company: 'Sanofi/Regeneron',
    indication: 'Chronic Obstructive Pulmonary Disease',
    indication_specifics: 'Moderate-to-severe COPD with type 2 inflammation (elevated blood eosinophils) as add-on maintenance therapy',
    mechanism: 'Monoclonal antibody targeting IL-4 receptor alpha, blocking IL-4 and IL-13 type 2 inflammatory signaling',
    mechanism_category: 'anti_il4_il13',
    phase: 'Approved',
    primary_endpoint: 'Annualized rate of moderate or severe COPD exacerbations',
    key_data: 'BOREAS Phase 3: 30% reduction in moderate/severe exacerbations in COPD patients with eosinophils >=300 cells/uL. Significant FEV1 improvement (+160 mL). FDA approved for COPD Sept 2024.',
    line_of_therapy: 'Add-on to maximal inhaled therapy (LABA/LAMA/ICS)',
    partner: 'Regeneron',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'First biologic approved for COPD, opening a new treatment paradigm for type 2-high patients',
      'Demonstrated both exacerbation reduction and lung function improvement in COPD',
      'Extensive safety track record from atopic dermatitis and asthma indications',
    ],
    weaknesses: [
      'Requires eosinophil biomarker selection (>=300 cells/uL), limiting addressable COPD population',
      'Biologic pricing in a disease affecting tens of millions creates significant payer pushback',
      'Subcutaneous injection every 2 weeks less convenient than inhaled therapies for COPD patients',
    ],
    source: 'Sanofi/Regeneron 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Trelegy Ellipta',
    generic_name: 'fluticasone furoate/umeclidinium/vilanterol',
    company: 'GSK',
    indication: 'Chronic Obstructive Pulmonary Disease',
    indication_specifics: 'Maintenance treatment of COPD in patients on LABA/LAMA or ICS/LABA requiring additional bronchodilation or exacerbation reduction',
    mechanism: 'Fixed-dose triple combination inhaler combining ICS (fluticasone), LAMA (umeclidinium), and LABA (vilanterol) for comprehensive airway management',
    mechanism_category: 'triple_combination_inhaler',
    phase: 'Approved',
    primary_endpoint: 'Annual rate of moderate/severe COPD exacerbations and lung function (FEV1)',
    key_data: 'IMPACT Phase 3: 25% reduction in moderate/severe exacerbations vs LAMA/LABA dual therapy. Mortality benefit demonstrated for ICS-containing triple therapy. Market-leading COPD inhaler.',
    line_of_therapy: 'Maintenance therapy for moderate-to-severe COPD',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'First once-daily single-inhaler triple therapy, maximizing patient adherence and convenience',
      'Mortality reduction demonstrated in IMPACT trial, a unique differentiator among inhalers',
      'Market-leading position with established formulary access and physician familiarity',
    ],
    weaknesses: [
      'ICS component carries pneumonia risk in COPD patients, a well-documented class concern',
      'Increasing generic competition as patents expire and biosimilar inhalers emerge',
      'Does not address underlying disease biology or modify long-term disease progression',
    ],
    source: 'GSK 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Ensifentrine',
    company: 'Verona Pharma',
    indication: 'Chronic Obstructive Pulmonary Disease',
    indication_specifics: 'Maintenance treatment of COPD as an inhaled dual PDE3/PDE4 inhibitor with both bronchodilator and anti-inflammatory properties',
    mechanism: 'Dual phosphodiesterase 3 and 4 (PDE3/PDE4) inhibitor delivered via nebulization; combines bronchodilation (PDE3) with anti-inflammatory effects (PDE4)',
    mechanism_category: 'pde3_4_inhibitor',
    phase: 'Approved',
    primary_endpoint: 'Change in FEV1 from baseline (average of 0-12 hour post-dose)',
    key_data: 'ENHANCE-1/2 Phase 3: Significant improvement in FEV1 vs placebo. Reduced moderate/severe exacerbations by 36%. FDA approved June 2024 as first inhaled PDE inhibitor for COPD.',
    line_of_therapy: 'Maintenance therapy, add-on to existing bronchodilators',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'First-in-class inhaled dual PDE3/4 inhibitor offering novel mechanism orthogonal to existing therapies',
      'Combines bronchodilation and anti-inflammatory effects in a single inhaled molecule',
      'Avoids systemic PDE4 inhibitor side effects (nausea, weight loss) through inhaled delivery',
    ],
    weaknesses: [
      'Nebulized delivery is less convenient than metered-dose or dry-powder inhalers',
      'Novel drug class with limited long-term real-world safety and durability data',
      'Modest absolute FEV1 improvement compared to established bronchodilator combinations',
    ],
    source: 'Verona Pharma 2024',
    last_updated: '2025-01-15',
  },

  // ─── Bronchiectasis ───────────────────────────────────────────────────
  {
    asset_name: 'Brensocatib',
    company: 'AstraZeneca',
    indication: 'Bronchiectasis',
    indication_specifics: 'Non-cystic fibrosis bronchiectasis characterized by neutrophilic airway inflammation',
    mechanism: 'Oral dipeptidyl peptidase 1 (DPP1) inhibitor that blocks activation of neutrophil serine proteases in bone marrow, reducing neutrophil-driven airway damage',
    mechanism_category: 'dpp1_inhibitor',
    molecular_target: 'DPP1',
    phase: 'Phase 3',
    primary_endpoint: 'Annualized rate of pulmonary exacerbations',
    key_data: 'ASPEN Phase 3: Met primary endpoint with significant reduction in pulmonary exacerbations vs placebo. Reduced active neutrophil elastase by >90%. Regulatory submissions planned 2025.',
    line_of_therapy: 'Maintenance therapy',
    nct_ids: ['NCT04594369'],
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'First-in-class oral therapy targeting the root cause of neutrophilic airway damage',
      'Positive Phase 3 ASPEN results de-risk regulatory path; potential first approved bronchiectasis therapy',
      'Oral once-daily dosing far more convenient than inhaled antibiotics',
    ],
    weaknesses: [
      'Systemic DPP1 inhibition may impair innate immune defense and increase infection risk',
      'Long-term safety of chronic neutrophil protease suppression remains uncertain',
      'Dental adverse events (gingivitis, periodontitis) observed as class-related side effects',
    ],
    source: 'AstraZeneca 2025',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Colistimethate sodium inhaled',
    company: 'Zambon',
    indication: 'Bronchiectasis',
    indication_specifics: 'Chronic Pseudomonas aeruginosa airway infection in adults with non-cystic fibrosis bronchiectasis',
    mechanism: 'Inhaled polymyxin antibiotic with bactericidal activity against gram-negative pathogens via cell membrane disruption',
    mechanism_category: 'inhaled_antibiotic',
    phase: 'Approved',
    primary_endpoint: 'Annualized rate of exacerbations',
    key_data: 'PROMIS-I/II Phase 3: Approved in EU for Pseudomonas-colonized bronchiectasis patients. Demonstrated reduction in bacterial load and exacerbation frequency in chronic Pseudomonas infection.',
    line_of_therapy: 'Maintenance suppressive therapy for chronic Pseudomonas infection',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'EU approval provides validated treatment option for Pseudomonas-colonized bronchiectasis patients',
      'Inhaled delivery achieves high airway drug concentrations with limited systemic exposure',
      'Addresses a clear microbiological target in pathogen-defined patient population',
    ],
    weaknesses: [
      'Limited to Pseudomonas-positive patients, a subset of the bronchiectasis population',
      'Nebulized delivery is time-consuming and requires regular equipment maintenance',
      'Not approved in the US, limiting global commercial reach',
    ],
    source: 'Zambon 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Arikayce',
    generic_name: 'amikacin liposome inhalation suspension',
    company: 'Insmed',
    indication: 'Bronchiectasis',
    indication_specifics: 'Mycobacterium avium complex (MAC) lung disease in adults with limited treatment options, often comorbid with bronchiectasis',
    mechanism: 'Liposomal formulation of amikacin for nebulized inhalation; liposomal delivery enhances uptake by alveolar macrophages harboring intracellular MAC organisms',
    mechanism_category: 'inhaled_antibiotic',
    phase: 'Approved',
    primary_endpoint: 'Sputum culture conversion by month 6 maintained through 12 months of treatment',
    key_data: 'CONVERT Phase 3: 29% culture conversion rate vs 9% with guideline-based therapy alone in refractory MAC. FDA approved 2018 under accelerated pathway, full approval 2023.',
    line_of_therapy: 'Add-on to guideline-based multidrug regimen for refractory MAC',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'First and only FDA-approved inhaled therapy specifically for MAC lung disease',
      'Liposomal formulation enables enhanced macrophage uptake at the site of intracellular infection',
      'Full FDA approval achieved in 2023 based on confirmatory post-marketing data',
    ],
    weaknesses: [
      'Narrow indication limited to MAC lung disease, not broadly approved for bronchiectasis',
      'Requires specialized nebulizer (Lamira) and daily nebulization sessions of ~15 minutes',
      'Ototoxicity and nephrotoxicity risks inherent to aminoglycoside class require monitoring',
    ],
    source: 'Insmed 2024',
    last_updated: '2025-01-15',
  },

  // ─── IgA Nephropathy ──────────────────────────────────────────────────
  {
    asset_name: 'Filspari',
    generic_name: 'sparsentan',
    company: 'Travere Therapeutics',
    indication: 'IgA Nephropathy',
    indication_specifics: 'IgA nephropathy at risk of rapid disease progression based on proteinuria >=1 g/day despite RAS inhibition',
    mechanism: 'Dual endothelin type A and angiotensin II type 1 receptor antagonist; reduces proteinuria through complementary hemodynamic and anti-inflammatory mechanisms',
    mechanism_category: 'endothelin_angiotensin_inhibitor',
    phase: 'Approved',
    primary_endpoint: 'Proteinuria reduction (urine protein-to-creatinine ratio) at 36 weeks',
    key_data: 'PROTECT Phase 3: 49% reduction in proteinuria vs irbesartan at 36 weeks. Accelerated FDA approval Feb 2023 based on proteinuria as surrogate endpoint. Confirmatory eGFR outcomes pending.',
    line_of_therapy: 'First-line for high-risk IgA nephropathy',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'First FDA-approved therapy specifically for IgA nephropathy, addressing major unmet need',
      'Dual receptor antagonism provides superior proteinuria reduction vs single-target RAS blockade',
      'Oral once-daily dosing with familiar mechanism class (ARB/ERA) for nephrologists',
    ],
    weaknesses: [
      'Accelerated approval based on proteinuria surrogate; confirmatory eGFR slope data still maturing',
      'Endothelin receptor antagonism carries fluid retention, hepatotoxicity, and teratogenicity risks',
      'REMS program required due to teratogenic potential, adding prescribing burden',
    ],
    source: 'Travere Therapeutics 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Tarpeyo',
    generic_name: 'budesonide delayed-release capsules',
    company: 'Calliditas Therapeutics/Strides Pharma',
    indication: 'IgA Nephropathy',
    indication_specifics: 'IgA nephropathy at risk of rapid disease progression in adults with proteinuria >=1 g/day',
    mechanism: 'Targeted-release oral budesonide formulation designed to deliver corticosteroid to the distal ileum Peyer patches where IgA is produced, suppressing mucosal IgA immune response',
    mechanism_category: 'targeted_release_corticosteroid',
    phase: 'Approved',
    primary_endpoint: 'Proteinuria reduction (UPCR) at 9 months and eGFR slope over 2 years',
    key_data: 'NefIgArd Phase 3: 34% reduction in proteinuria vs placebo at 9 months. Full approval Dec 2023 based on eGFR stabilization over 2 years, demonstrating kidney function preservation.',
    line_of_therapy: 'First-line or add-on to RAS inhibition',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Full FDA approval based on eGFR outcomes, not just surrogate proteinuria endpoint',
      'Targeted gut delivery minimizes systemic corticosteroid exposure compared to oral prednisone',
      'Well-understood budesonide active ingredient with extensive clinical safety history',
    ],
    weaknesses: [
      'Corticosteroid-related adverse effects (acne, weight gain, mood changes) still occur despite targeted delivery',
      'Limited 9-month treatment course requires re-evaluation; unclear optimal retreatment strategy',
      'Proteinuria reduction magnitude (34%) is less than sparsentan (49%) in cross-trial comparisons',
    ],
    source: 'Calliditas Therapeutics 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Atrasentan',
    company: 'Chinook Therapeutics/Novartis',
    indication: 'IgA Nephropathy',
    indication_specifics: 'IgA nephropathy with persistent proteinuria despite maximum tolerated RAS inhibition',
    mechanism: 'Selective endothelin type A (ETA) receptor antagonist; reduces proteinuria by attenuating endothelin-mediated podocyte injury and glomerular hemodynamic dysfunction',
    mechanism_category: 'endothelin_receptor_antagonist',
    phase: 'Phase 3',
    primary_endpoint: 'Proteinuria reduction (UPCR) and eGFR slope',
    key_data: 'ALIGN Phase 3: Met primary endpoint with 38% greater proteinuria reduction vs placebo at 36 weeks. Supportive eGFR slope benefit observed. NDA submission planned 2025.',
    line_of_therapy: 'First-line or add-on therapy',
    nct_ids: ['NCT04573478'],
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Highly selective ETA antagonism may offer better tolerability than dual ET/AT receptor blockers',
      'Positive Phase 3 ALIGN results support regulatory path with strong proteinuria reduction',
      'Novartis acquisition provides robust global development and commercial infrastructure',
    ],
    weaknesses: [
      'Endothelin antagonist class carries fluid retention risk requiring careful monitoring',
      'Late to market behind two approved IgAN therapies (Filspari, Tarpeyo)',
      'Hepatotoxicity and teratogenicity concerns inherent to ERA class require REMS-like safeguards',
    ],
    source: 'Novartis 2024',
    last_updated: '2025-01-15',
  },

  // ─── Lupus Nephritis ──────────────────────────────────────────────────
  {
    asset_name: 'Lupkynis',
    generic_name: 'voclosporin',
    company: 'Aurinia Pharmaceuticals',
    indication: 'Lupus Nephritis',
    indication_specifics: 'Active class III, IV, or V lupus nephritis in combination with background immunosuppressive therapy',
    mechanism: 'Novel calcineurin inhibitor (CNI) with structural modification for more predictable pharmacokinetics; inhibits T-cell activation and has direct podocyte-stabilizing effects',
    mechanism_category: 'calcineurin_inhibitor',
    phase: 'Approved',
    primary_endpoint: 'Complete renal response rate at 52 weeks',
    key_data: 'AURORA Phase 3: 41% complete renal response vs 23% placebo at 52 weeks (p<0.001). AURORA 2 extension showed durable response through 3 years. FDA approved Jan 2021.',
    line_of_therapy: 'Add-on to mycophenolate and corticosteroids',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'First oral therapy specifically approved for lupus nephritis with rapid onset of proteinuria reduction',
      'No therapeutic drug monitoring required unlike tacrolimus, simplifying clinical management',
      'Dual mechanism combining immunosuppression with direct podocyte stabilization',
    ],
    weaknesses: [
      'Calcineurin inhibitor class carries nephrotoxicity risk, complicating use in renal disease',
      'Twice-daily dosing with multiple capsules adds pill burden to complex immunosuppressive regimens',
      'Long-term renal safety data still accumulating; CNI nephrotoxicity may limit chronic use',
    ],
    source: 'Aurinia Pharmaceuticals 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Benlysta',
    generic_name: 'belimumab',
    company: 'GSK',
    indication: 'Lupus Nephritis',
    indication_specifics: 'Active lupus nephritis in combination with standard therapy in adults',
    mechanism: 'Monoclonal antibody targeting B-lymphocyte stimulator (BLyS/BAFF); reduces B-cell survival and autoantibody production driving lupus nephritis',
    mechanism_category: 'anti_baff',
    phase: 'Approved',
    primary_endpoint: 'Primary efficacy renal response (PERR) at week 104',
    key_data: 'BLISS-LN Phase 3: 43% PERR at 2 years vs 32% placebo. Significant reduction in renal-related events and flares. FDA approved for lupus nephritis Dec 2020.',
    line_of_therapy: 'Add-on to standard immunosuppressive therapy',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'First biologic approved for both SLE and lupus nephritis, providing comprehensive lupus treatment',
      'Available as both IV and subcutaneous formulation for flexible administration',
      'Long-term safety data spanning 10+ years of post-marketing experience in SLE',
    ],
    weaknesses: [
      'Modest absolute difference in renal response rates (~11% over placebo) at 2 years',
      'Slow onset of action requiring months to observe clinical benefit in active nephritis',
      'Biologic cost and injection/infusion burden in patients already on complex treatment regimens',
    ],
    source: 'GSK 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Obinutuzumab',
    company: 'Roche/Genentech',
    indication: 'Lupus Nephritis',
    indication_specifics: 'Proliferative lupus nephritis (class III/IV) with or without membranous features, targeting B-cell depletion',
    mechanism: 'Type II glycoengineered anti-CD20 monoclonal antibody with enhanced antibody-dependent cellular cytotoxicity; depletes B-cells more effectively than rituximab',
    mechanism_category: 'anti_cd20',
    phase: 'Phase 3',
    primary_endpoint: 'Complete renal response at 52 weeks',
    key_data: 'NOBILITY Phase 2: 35% complete renal response vs 23% placebo at 2 years. Superior B-cell depletion vs rituximab. Phase 3 REGENCY trial ongoing in proliferative lupus nephritis.',
    line_of_therapy: 'Add-on to standard immunosuppressive therapy',
    nct_ids: ['NCT04221477'],
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Enhanced B-cell depletion vs rituximab through glycoengineered Fc portion',
      'Already approved in oncology (CLL, FL) with well-characterized safety profile',
      'Promising Phase 2 NOBILITY data showing durable renal responses at 2 years',
    ],
    weaknesses: [
      'IV infusion requirement with infusion reactions is burdensome for chronic disease management',
      'Profound B-cell depletion increases infection risk, particularly in immunosuppressed lupus patients',
      'Phase 3 results not yet available; prior anti-CD20 rituximab failed Phase 3 in lupus nephritis',
    ],
    source: 'Roche 2024',
    last_updated: '2025-01-15',
  },

  // ─── Focal Segmental Glomerulosclerosis ───────────────────────────────
  {
    asset_name: 'Sparsentan',
    company: 'Travere Therapeutics',
    indication: 'Focal Segmental Glomerulosclerosis',
    indication_specifics: 'Primary focal segmental glomerulosclerosis with proteinuria despite RAS inhibition',
    mechanism: 'Dual endothelin type A and angiotensin II type 1 receptor antagonist; reduces proteinuria through hemodynamic and anti-fibrotic mechanisms at the glomerulus',
    mechanism_category: 'endothelin_angiotensin_inhibitor',
    phase: 'Phase 3',
    primary_endpoint: 'Partial remission of proteinuria (UPCR <=1.5 g/g and >=40% reduction)',
    key_data: 'DUPLEX Phase 3: Significant reduction in proteinuria vs irbesartan at 36 weeks. Long-term eGFR data pending for confirmatory endpoint.',
    line_of_therapy: 'First-line for proteinuric FSGS',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'Dual receptor mechanism addresses both hemodynamic and fibrotic drivers of FSGS progression',
      'Orphan drug designation provides regulatory and commercial incentives in rare kidney disease',
      'Leverages IgAN clinical and regulatory experience from same compound (Filspari)',
    ],
    weaknesses: [
      'FSGS is highly heterogeneous; genetic, adaptive, and immune-mediated forms may respond differently',
      'Confirmatory eGFR slope data still maturing; proteinuria as surrogate is debated in FSGS',
      'Teratogenicity requires strict contraception and REMS, limiting use in young patients',
    ],
    source: 'Travere Therapeutics 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Inaxaplin',
    company: 'Vertex Pharmaceuticals',
    indication: 'Focal Segmental Glomerulosclerosis',
    indication_specifics: 'APOL1-mediated FSGS in patients carrying two APOL1 risk variants (G1/G2)',
    mechanism: 'Small molecule APOL1 inhibitor; blocks pathological gain-of-function activity of APOL1 risk variants that cause podocyte toxicity and kidney damage',
    mechanism_category: 'apol1_inhibitor',
    phase: 'Phase 2/3',
    primary_endpoint: 'Proteinuria reduction (UPCR) at 48 weeks',
    key_data: 'Phase 2: Demonstrated significant proteinuria reduction in APOL1-mediated FSGS patients carrying two risk variants. First precision medicine approach targeting APOL1 in kidney disease.',
    line_of_therapy: 'First-line for APOL1-mediated FSGS',
    nct_ids: ['NCT05267262'],
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'First-in-class precision medicine approach targeting the genetic root cause of APOL1-mediated kidney disease',
      'Clear biomarker selection (APOL1 genotyping) identifies patients most likely to respond',
      'Addresses significant health disparity as APOL1 variants disproportionately affect patients of African descent',
    ],
    weaknesses: [
      'Limited to APOL1 two-risk-variant carriers (~13% of African Americans), narrowing addressable population',
      'APOL1 has protective function against trypanosomal infection; long-term inhibition safety unknown',
      'Phase 2/3 data still maturing; magnitude and durability of proteinuria reduction to be confirmed',
    ],
    source: 'Vertex Pharmaceuticals 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Atacicept',
    company: 'Vera Therapeutics',
    indication: 'Focal Segmental Glomerulosclerosis',
    indication_specifics: 'Primary FSGS with immune-mediated pathogenesis involving B-cell and plasma cell dysregulation',
    mechanism: 'Recombinant fusion protein that blocks both BAFF and APRIL cytokines; inhibits B-cell maturation and plasma cell survival to reduce pathogenic immunoglobulin production',
    mechanism_category: 'anti_baff_april',
    phase: 'Phase 3',
    primary_endpoint: 'Proteinuria reduction (UPCR) and eGFR slope',
    key_data: 'Advancing into Phase 3 for FSGS based on mechanism of action rationale from IgAN data. ORIGIN Phase 3 trial in IgAN showed 52% proteinuria reduction, supporting B-cell pathway targeting in glomerulopathies.',
    line_of_therapy: 'First-line or add-on to immunosuppression',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'Dual BAFF/APRIL blockade provides broader B-cell and plasma cell suppression than single-target approaches',
      'Subcutaneous self-administration offers convenience over IV infusion biologics',
      'Orphan drug designation and strong IgAN data support immune-mediated glomerular disease rationale',
    ],
    weaknesses: [
      'FSGS pathogenesis is heterogeneous; not all forms are immune-mediated, limiting responder population',
      'IgG reduction may increase infection risk with long-term B-cell and plasma cell suppression',
      'Early development in FSGS with limited disease-specific clinical data available',
    ],
    source: 'Vera Therapeutics 2024',
    last_updated: '2025-01-15',
  },

  // ─── Acromegaly ───────────────────────────────────────────────────────
  {
    asset_name: 'Sandostatin LAR',
    generic_name: 'octreotide LAR',
    company: 'Novartis',
    indication: 'Acromegaly',
    indication_specifics: 'Acromegaly in patients who have had inadequate response to surgery or for whom surgery is not an option',
    mechanism: 'Long-acting somatostatin analog that binds SST2 and SST5 receptors; inhibits growth hormone and IGF-1 secretion from pituitary somatotroph adenomas',
    mechanism_category: 'somatostatin_analog',
    phase: 'Approved',
    primary_endpoint: 'Normalization of GH and IGF-1 levels',
    key_data: 'Established standard of care with ~65% biochemical response rate (IGF-1 normalization). Monthly IM injection with decades of clinical experience. Tumor shrinkage observed in ~50-70% of patients.',
    line_of_therapy: 'First-line medical therapy',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'Gold-standard therapy with decades of clinical experience and well-characterized safety profile',
      'High biochemical response rate with consistent IGF-1 normalization in majority of patients',
      'Demonstrated tumor volume reduction in addition to biochemical control',
    ],
    weaknesses: [
      'Monthly intramuscular injection requires healthcare professional administration',
      'GI side effects (diarrhea, abdominal pain, gallstones) occur in 20-30% of patients',
      'Approximately 35% of patients fail to achieve biochemical control, requiring additional therapy',
    ],
    source: 'Novartis 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Somatuline',
    generic_name: 'lanreotide',
    company: 'Ipsen',
    indication: 'Acromegaly',
    indication_specifics: 'Long-term treatment of acromegaly when surgery or radiotherapy is inadequate or as primary therapy',
    mechanism: 'Long-acting somatostatin analog with preferential SST2 binding; suppresses GH secretion and normalizes IGF-1 through somatostatin receptor activation',
    mechanism_category: 'somatostatin_analog',
    phase: 'Approved',
    primary_endpoint: 'Normalization of GH and IGF-1 levels',
    key_data: 'Comparable biochemical control rates to octreotide LAR (~60-65% IGF-1 normalization). Deep subcutaneous injection allows self-administration. Extended dosing intervals up to every 8 weeks possible in some patients.',
    line_of_therapy: 'First-line medical therapy',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'Self-injectable deep subcutaneous formulation eliminates need for clinic visits',
      'Comparable efficacy to octreotide LAR with potential for extended 6-8 week dosing intervals',
      'Available as prefilled syringe with automated injection device for patient convenience',
    ],
    weaknesses: [
      'Similar ~35% non-responder rate as other somatostatin analogs',
      'Injection site nodules and GI side effects (diarrhea, cholelithiasis) remain common',
      'Limited differentiation from octreotide LAR beyond route of administration',
    ],
    source: 'Ipsen 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Paltusotine',
    company: 'Crinetics Pharmaceuticals',
    indication: 'Acromegaly',
    indication_specifics: 'Acromegaly in patients currently controlled on injectable somatostatin receptor ligands, transitioning to oral therapy',
    mechanism: 'Oral nonpeptide selective somatostatin receptor type 2 (SST2) agonist; mimics somatostatin signaling to suppress GH and IGF-1 secretion without injection',
    mechanism_category: 'sst2_agonist',
    phase: 'Phase 3',
    primary_endpoint: 'Maintenance of IGF-1 control at 36 weeks after switching from injectable SRL',
    key_data: 'PATHFNDR Phase 3: Met primary endpoint — 84% of patients maintained IGF-1 control after switching from injectable SRL to oral paltusotine. Consistent GH suppression demonstrated.',
    line_of_therapy: 'First-line or switch from injectable somatostatin analogs',
    nct_ids: ['NCT05529849'],
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'First-in-class oral somatostatin receptor agonist eliminating injection burden entirely',
      'Positive Phase 3 results showing high rate of maintained biochemical control after switch',
      'Once-daily oral dosing represents paradigm shift for a disease requiring lifelong treatment',
    ],
    weaknesses: [
      'Phase 3 enrolled patients already controlled on injectables; unclear efficacy in treatment-naive or uncontrolled patients',
      'Oral bioavailability challenges inherent to peptide-mimetic compounds may limit dose flexibility',
      'Regulatory pathway and pricing vs established generic octreotide remain uncertain',
    ],
    source: 'Crinetics Pharmaceuticals 2025',
    last_updated: '2025-01-15',
  },

  // ─── Cushing Syndrome ─────────────────────────────────────────────────
  {
    asset_name: 'Isturisa',
    generic_name: 'osilodrostat',
    company: 'Recordati',
    indication: 'Cushing Syndrome',
    indication_specifics: 'Endogenous Cushing syndrome in adults for whom pituitary surgery is not an option or has not been curative',
    mechanism: 'Oral 11-beta-hydroxylase inhibitor; blocks the final step of cortisol biosynthesis in the adrenal gland, directly reducing cortisol production',
    mechanism_category: 'cortisol_synthesis_inhibitor',
    phase: 'Approved',
    primary_endpoint: 'Normalization of 24-hour urinary free cortisol (UFC) at 34 weeks',
    key_data: 'LINC 3/4 Phase 3: 86% of patients achieved normal UFC at week 48. Rapid onset of cortisol reduction within weeks. FDA approved March 2020 for Cushing disease.',
    line_of_therapy: 'Second-line after surgery or when surgery not feasible',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'Highest cortisol normalization rate (~86%) among approved medical therapies for Cushing syndrome',
      'Rapid onset of cortisol reduction with twice-daily oral dosing',
      'Directly targets cortisol synthesis providing predictable pharmacologic control',
    ],
    weaknesses: [
      'Adrenal insufficiency risk requires careful dose titration and cortisol monitoring',
      'QTc prolongation potential requires ECG monitoring, particularly during dose escalation',
      'Accumulation of cortisol precursors can cause hyperandrogenism (hirsutism, acne) in women',
    ],
    source: 'Recordati 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Korlym',
    generic_name: 'mifepristone',
    company: 'Corcept Therapeutics',
    indication: 'Cushing Syndrome',
    indication_specifics: 'Hyperglycemia secondary to endogenous hypercortisolism in patients with Cushing syndrome who have failed surgery or are not surgical candidates',
    mechanism: 'Competitive glucocorticoid receptor (GR) antagonist; blocks cortisol action at the receptor level without reducing cortisol levels, improving metabolic consequences of hypercortisolism',
    mechanism_category: 'glucocorticoid_receptor_antagonist',
    phase: 'Approved',
    primary_endpoint: 'Improvement in glucose tolerance (>=25% reduction in AUC glucose) or clinical improvement',
    key_data: 'SEISMIC Phase 3: 60% of patients with diabetes/glucose intolerance achieved >=25% reduction in glucose AUC. Significant improvements in weight, blood pressure, and clinical signs of Cushing.',
    line_of_therapy: 'Second-line for Cushing syndrome with hyperglycemia',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'First FDA-approved medical therapy for Cushing syndrome (2012), establishing treatment paradigm',
      'Unique receptor-level blockade addresses all tissues affected by cortisol excess simultaneously',
      'Robust clinical improvements in metabolic parameters (glucose, weight, blood pressure)',
    ],
    weaknesses: [
      'Cannot monitor cortisol levels for dose titration since mechanism blocks receptor, not production',
      'Anti-progesterone activity contraindicates use in pregnancy and may cause endometrial thickening',
      'Adrenal insufficiency difficult to detect biochemically due to receptor blockade mechanism',
    ],
    source: 'Corcept Therapeutics 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Relacorilant',
    company: 'Corcept Therapeutics',
    indication: 'Cushing Syndrome',
    indication_specifics: 'Endogenous Cushing syndrome with selective glucocorticoid receptor modulation sparing progesterone receptor activity',
    mechanism: 'Selective glucocorticoid receptor modulator; antagonizes cortisol signaling at the GR while sparing progesterone, androgen, and mineralocorticoid receptors',
    mechanism_category: 'selective_gr_modulator',
    phase: 'Phase 3',
    primary_endpoint: 'Clinical response based on improvement in Cushing-specific comorbidities',
    key_data: 'GRACE Phase 3: Met primary endpoint demonstrating significant clinical improvement in hypertension, hyperglycemia, and body composition vs placebo. Improved safety profile vs mifepristone due to GR selectivity.',
    line_of_therapy: 'Second-line medical therapy',
    nct_ids: ['NCT03697109'],
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'Selective GR modulation avoids anti-progesterone effects (endometrial thickening, contraindication in pregnancy)',
      'Positive Phase 3 GRACE data supports differentiation from mifepristone on safety',
      'Same company (Corcept) provides seamless portfolio transition and Cushing expertise',
    ],
    weaknesses: [
      'Same limitation as mifepristone: cortisol levels cannot be used to monitor treatment response',
      'Entering market against established Korlym franchise from the same company, creating cannibalization risk',
      'Small patient population in Cushing syndrome limits commercial potential despite orphan status',
    ],
    source: 'Corcept Therapeutics 2025',
    last_updated: '2025-01-15',
  },

  // ─── Chronic Kidney Disease ───────────────────────────────────────────
  {
    asset_name: 'Kerendia',
    generic_name: 'finerenone',
    company: 'Bayer',
    indication: 'Chronic Kidney Disease',
    indication_specifics: 'Chronic kidney disease associated with type 2 diabetes to reduce risk of eGFR decline, kidney failure, cardiovascular death, and heart failure',
    mechanism: 'Nonsteroidal selective mineralocorticoid receptor antagonist (MRA); blocks aldosterone-mediated inflammation and fibrosis in kidney and heart without steroidal side effects',
    mechanism_category: 'nonsteroidal_mra',
    molecular_target: 'MR',
    phase: 'Approved',
    primary_endpoint: 'Composite of kidney failure, sustained >=40% eGFR decline, or renal death',
    key_data: 'FIDELIO-DKD/FIGARO-DKD Phase 3: 23% reduction in composite kidney endpoint. 14% reduction in composite cardiovascular endpoint. First MRA to demonstrate dual cardiorenal protection in CKD with T2D.',
    line_of_therapy: 'Add-on to RAS inhibition and SGLT2 inhibitors',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'First nonsteroidal MRA with proven dual cardiorenal benefit in diabetic kidney disease',
      'Complementary mechanism enables combination with RAS inhibitors and SGLT2 inhibitors',
      'Lower hyperkalemia and gynecomastia risk vs steroidal MRAs (spironolactone/eplerenone)',
    ],
    weaknesses: [
      'Hyperkalemia remains a concern requiring potassium monitoring, especially with concomitant RAS blockade',
      'Currently limited to CKD with type 2 diabetes; broader CKD populations not yet approved',
      'Requires baseline potassium <5.0 mEq/L and eGFR thresholds, narrowing eligible population',
    ],
    source: 'Bayer 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Farxiga',
    generic_name: 'dapagliflozin',
    company: 'AstraZeneca',
    indication: 'Chronic Kidney Disease',
    indication_specifics: 'Chronic kidney disease at risk of progression regardless of diabetes status, to reduce eGFR decline, kidney failure, and cardiovascular and renal death',
    mechanism: 'Sodium-glucose cotransporter 2 (SGLT2) inhibitor; reduces glucose reabsorption in proximal tubule, providing hemodynamic, metabolic, and anti-inflammatory renoprotection',
    mechanism_category: 'sglt2_inhibitor',
    molecular_target: 'SGLT2',
    phase: 'Approved',
    primary_endpoint: 'Composite of sustained >=50% eGFR decline, kidney failure, cardiovascular death, or renal death',
    key_data: 'DAPA-CKD Phase 3: 39% reduction in primary composite kidney endpoint vs placebo. Benefit consistent regardless of diabetes status. Trial stopped early for overwhelming efficacy.',
    line_of_therapy: 'First-line for CKD with or without T2D',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Robust 39% kidney event reduction with benefit in both diabetic and non-diabetic CKD patients',
      'Trial stopped early for efficacy, demonstrating compelling and unambiguous benefit',
      'Oral once-daily dosing with well-established safety profile from diabetes and heart failure programs',
    ],
    weaknesses: [
      'Genital mycotic infections and rare DKA risk remain class-associated safety concerns',
      'Diminishing eGFR benefit at very low kidney function (eGFR <20), limiting use in advanced CKD',
      'Competitive SGLT2 inhibitor market with empagliflozin (Jardiance) offering similar kidney data',
    ],
    source: 'AstraZeneca 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Jesduvroq',
    generic_name: 'daprodustat',
    company: 'GSK',
    indication: 'Chronic Kidney Disease',
    indication_specifics: 'Anemia of chronic kidney disease in adults on dialysis, as an alternative to injectable erythropoiesis-stimulating agents',
    mechanism: 'Oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI); stabilizes HIF to stimulate endogenous erythropoietin production and improve iron metabolism',
    mechanism_category: 'hif_phi',
    molecular_target: 'HIF-PHD',
    phase: 'Approved',
    primary_endpoint: 'Hemoglobin change from baseline and cardiovascular safety (MACE non-inferiority)',
    key_data: 'ASCEND Phase 3 program: Non-inferior to darbepoetin alfa for hemoglobin correction and MACE events. FDA approved Feb 2023 for CKD anemia on dialysis. First oral erythropoiesis agent approved in US.',
    line_of_therapy: 'Alternative to injectable ESAs for dialysis patients',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'First oral alternative to injectable ESAs, eliminating injection burden for dialysis patients',
      'Physiologic mechanism stimulating endogenous EPO production with improved iron utilization',
      'Cardiovascular safety non-inferior to darbepoetin alfa in comprehensive ASCEND MACE analysis',
    ],
    weaknesses: [
      'Currently approved only for dialysis patients; non-dialysis CKD anemia approval not yet secured in US',
      'HIF pathway activation raises theoretical concerns about tumor promotion and pulmonary hypertension',
      'Thromboembolic events observed across HIF-PHI class require ongoing pharmacovigilance',
    ],
    source: 'GSK 2024',
    last_updated: '2025-01-15',
  },
];
